

(43) International Publication Date 11 November 2004 (11.11.2004)

PCT

(10) International Publication Number WO 2004/096131 A3

(51) International Patent Classification⁷: A61K 31/445, C07D 401/14

(21) International Application Number:

PCT/US2004/012188

(22) International Filing Date: 20 April 2004 (20.04.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/465,260

24 April 2003 (24.04.2003) US

- (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BILODEAU, Mark, T. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). DUGGAN, Mark, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). HARTNETT, John, C. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). LINDSLEY, Craig, W. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 0706-0907 (US). WU, Zhicai [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). ZHAO, Zhijian [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 3 November 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF AKT ACTIVITY

(57) Abstract: The present invention is directed to compounds which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/12188

A. CLASSIFICATION OF SUBJECT MATTER				
IPC(7) : A61K 31/445; C07D 401/14				
US CL: 514/322; 546/199 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 514/322; 546/199				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet				
C. DOCU	IMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.	
Category *	Citation of document, with indication, where ap	propriate, of the relevant passages	1-8, 15-18	
X,E	Database CAPLUS on STN (Columbus, OH, USA) N trisubstituted pyridine derivatives as potent Akt1 and al. Biorganic & Medicinal Chemistry Letters (2005),	Akt2 dual inhibitors" agstract, Zhao et	1-6, 15-10	
A,P	Database CAPLUS on STN (Columbus, OH, USA) No. 139:350754 Preparation of 2,3-diphenylquinoxaline derivatives as inhibitors of Akt activity for treating cancer' abstract, Bilodeau et al. WO 2003086394, (2003).		1-8, 15-18	
A,P	Database CAPLUS on STN (Columbus, OH, USA) No. 139:323527, 'preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer' Barnett et al. WO 2003084473 (2003).		1-8, 15-18	
	·			
Further documents are listed in the continuation of Box C. See patent family annex.				
Special categories of cited documents: T" later document published after the international filing date or priority of and not in conflict with the application but cited to understand the			stional filing date or priority date ut cited to understand the	
"A" document defining the general state of the art which is not considered to be of principle or theory underlying the invention			ion	
,	plication or patent published on or after the international filing date	"X" document of particular relevance; the cia considered novel or cannot be considere when the document is taken alone	d to involve an inventive step	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as "Y" document of considered to		considered to involve an inventive step	when the document is combined	
specified) with one or more other such documents, such combination being obvious to a person skilled in the art				
"P" document published prior to the international filing date but later than the "&" document member of the same patent family priority date claimed				
Date of the actual completion of the international search Date of mailing of the international search report				
Name and mailing address of the ISA/US Adinofized officer Adinofized officer				
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450				
Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230				

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/12188

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)	
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:		
ı. 🗀	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:	
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:	
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)		
This Internal Please See C	ional Searching Authority found multiple inventions in this international application, as follows: Continuation Sheet	
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.	
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:	
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7, 15-18 in part reading on claim 8	
Remark on Protest The additional search fees were accompanied by the applicant's protest.		

INTERNATIONAL SEARCH REPORT

International application No. PCT/US04/12188

BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

Group I, claims 1-7, 15-18 when Q is benzimidazolone, N-ring is piperidine and claim 8, drawn to benzimidazolonylpiperidines.

Group II, claims 1-7, 15-18 when Q is 2-benzimidazole, N-ring is piperidine and claims 9, 12, drawn to 2-benzimidazolylpiperidines.

Group III, claims 1-7, 15-18 when Q is pyridinylpyrazole, drawn to pyridinylpyrazoles.

Group IV, claims 1-7, 15-18, Q is pyrimidinylpyrazole, and claims 11, 13-14 drawn to pyrimidinylpyrazoles.

Group V, claims 1-7, 15-18 while Q is alkyl, halogen etc, excluding groups I-IV, drawn to unsubstituted/substituted N-heterocyclic compounds not encompassed by groups I-IV.

Group VI, claim 19, drawn to multiple active ingredient composition.

Group VII, claim 20, drawn to method of treating cancer using combination of drug and radiation.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: PCT Annex B part (f)v indicates that when dealing with alternatives if it can be shown that at least one Markush alternative is not novel over the art the question of unity of invention shall be reconsidered by the examiner. In the instant case, at least one Markush alternative is not novel over Bilodeau et al. Ca 139:350754.

Continuation of B. FIELDS SEARCHED Item 3:

CAS-structure EAST/WEST-image